Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase NA 2Phase EARLY_PHASE1 2Phase 4 1Phase 3 1

Status

Unknown 5Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 20Carcinoma, Hepatocellular 8Stomach Neoplasms 6Multiple Myeloma 6Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Lung Neoplasms 3Febrile Neutropenia 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 2Venous Thromboembolism 2Skin Neoplasms 2Pancreatic Neoplasms 2Pancreatic Cancer Non-resectable 2Obesity 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hepatitis B 2Hematologic Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Anemia 2Acute Kidney Injury 2

Interventions

lorlatinib 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × NSCLC × Clear all
NCT06893354 2025-03-25

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

The First Affiliated Hospital of Guangzhou Medical University

Phase 4 Not yet recruiting
20 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡